Fibromyalgia Treatment Market Size, Share, Growth Analysis, By Drug class(Antidepressants, Antiepileptic), By Distribution Channels(Hospital pharmacies, Retail pharmacies) - Industry Forecast 2024-2031

Drivers

Rise in the Fibromyalgia

• Various factors affect the growth of the global fibromyalgia treatment market, primarily due to the increasing prevalence of fibromyalgia worldwide. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), about five million people aged 18 and after and have fibromyalgia in the US. It is worth noting that 80 to 90 percent of fibromyalgia patients are mostly women. This sex-specific prevalence highlights the significant impact of fibromyalgia on the female population. Increasing awareness of fibromyalgia and improved diagnostic capabilities are contributing to greater acceptance of the issues worldwide.

Restraints

Use of Non-Pharmaceutical Drugs and Superior Pharmaceuticals

• The limited availability of drugs specifically approved for the treatment of fibromyalgia has now led to only three, despite this increasing reliance on off-label medications and customized antidepressants to address the symptoms of the disease. In June 2019, Pfizer the loss of patent protection for Lyrica, the first drug in the treatment of fibromyalgia, had a significant impact on the drug’s market revenue. While patent protection expired, the generic Lyrica entered the market, increasing competition and subsequent decline in the overall market.